

---

## DEFINITIONS

---

*In this Prospectus, unless the context otherwise requires, the following terms shall have the meanings set out below. Certain other terms are explained in “Glossary of Technical Terms” of this Prospectus.*

“3DMed”	3D Medicines (Beijing) Co., Ltd. (思路迪(北京)醫藥科技有限公司), a company incorporated under the laws of the PRC on December 22, 2014, an Independent Third Party collaborating with us in the development of KN035
“Advantech I”	Advantech Capital Investment I Limited, a company incorporated in the Cayman Islands and one of our Pre-IPO Investors
“Advantech II”	Advantech Capital II AlphaMab Partnership L.P., a limited partnership registered in the Cayman Islands and one of our Pre-IPO Investors
“Aljade”	Aljade Ltd., a company incorporated in the BVI on July 11, 2018 and owned by Suzhou Zhongning and Suzhou Yuning as to 50%, respectively
“Alphamab Australia”	Alphamab (Australia) Co Pty Ltd, a company incorporated in Australia on November 20, 2017 and a direct wholly-owned subsidiary of Jiangsu Alphamab
“Alphamab Oncology (BVI)”	Alphamab Oncology (BVI) Ltd., a business company incorporated in the BVI and a direct wholly-owned subsidiary of our Company
“Alphamab Oncology (HK)”	Alphamab Oncology (HK) Limited, a limited liability company incorporated in Hong Kong on May 11, 2018
“Application Form(s)”	<b>WHITE</b> Application Form(s), <b>YELLOW</b> Application Form(s) and <b>GREEN</b> Application Form(s), or where the context so requires, any of them, relating to the Hong Kong Public Offering
“Articles of Association” or “Articles”	articles of association of our Company conditionally adopted on November 24, 2019 with effect from the Listing Date, a summary of which is set out in “Appendix IV—Summary of the Constitution of the Company and Cayman Islands Company Law” to this Prospectus

---

## DEFINITIONS

---

“Asset Transfer and Patent Licensing Agreements”	an asset transfer and patent licensing agreement (資產轉讓及專利實施許可合同) entered into between Suzhou Alphamab and Jiangsu Alphamab on April 18, 2018, together with three supplemental agreements entered into by the same parties on June 26, 2018, December 26, 2018 and February 27, 2019, respectively
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“AstraZeneca”	AstraZeneca plc, a British multi-national pharmaceutical and biopharmaceutical company
“BLA”	biologic license application
“BMS”	Bristol-Myers Squibb, a U.S. multi-national pharmaceutical company
“Board”	the board of directors of our Company
“Business Day”	a day on which banks in Hong Kong are generally open for normal banking business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong
“BVI”	the British Virgin Islands
“CAGR”	compound annual growth rate
“CCASS”	the Central Clearing and Settlement System established and operation by HKSCC
“CCASS Clearing Participant”	a person admitted to participate in CCASS as a direct clearing participant or general clearing participant
“CCASS Custodian Participant”	a person admitted to participate in CCASS as a custodian participant
“CCASS Investor Participant”	a person admitted to participate in CCASS as an investor participant who may be an individual or joint individuals or a corporation
“CCASS Operational Procedures”	the operational procedures of HKSCC in relation to CCASS, containing the practices, procedures and administrative requirements relating to the operation and functions of CCASS, as from time to time in force

---

## DEFINITIONS

---

“CCASS Participant”	a CCASS Clearing Participant, a CCASS Custodian Participant or a CCASS Investor Participant
“CDA”	China Drug Administration (國家藥品監督管理總局)
“CDE”	Center for Drug Evaluation (藥品審評中心)
“China,” “mainland China,” “PRC” or “State”	People’s Republic of China, but for the purpose of this Prospectus and for geographical reference only and except where the context requires otherwise, references in this Prospectus to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“CIC”	China Insights Consultancy Limited
“CIC Report”	the market research report prepared by CIC and commissioned by us
“Circular 7”	Announcement on Issues of Enterprising Income Tax Arising from Indirect Property Transfer Between Non-resident Enterprises (關於非居民企業間接轉讓財產企業所得稅若干問題的公告)
“Circular 37”	SAFE Circular on Relevant Issues Relating to the Administration of Foreign Exchange on Domestic Resident’s Overseas Investment and Financing and Roundtrip Investment through Special Purpose Vehicles (國家外匯管理局關於境內居民通過特殊目的公司境外投資及返程投資外匯管理有關問題的通知)
“Classic Insight”	Classic Insight Project Company Limited, a company incorporated in the BVI and one of our Pre-IPO Investors
“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“CNIPA”	National Intellectual Property Administration of the PRC
“Co-development Agreements”	a co-development agreement entered into between 3DMed and us in relation to KN035 in February 2016, together with a series of other supplemental agreements entered into by the same parties from 2017 to 2019

---

## DEFINITIONS

---

“Companies Law” or “Cayman Companies Law”	the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands, as amended, supplemented or otherwise modified from time to time
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance, Chapter 32 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
“Company”, “our Company” or “the Company”	Alphamab Oncology (康寧傑瑞生物製藥), an exempted company with limited liability incorporated under the laws of the Cayman Islands on March 28, 2018
“connected person”	has the meaning ascribed thereto under the Listing Rules
“connected transaction”	has the meaning ascribed thereto under the Listing Rules
“Controlling Shareholder(s)”	has the meaning ascribed thereto under the Listing Rules and unless the context requires otherwise, refers to Dr. Xu and/or Rubymab
“Core Product”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purposes of this Prospectus, our Core Product refers to KN046
“Data Cut-off Date”	September 13, 2019 for KN046 and KN019
“Director(s)” or “our Director(s)”	the directors of our Company, including all executive, non-executive and independent non-executive directors
“Dr. Xu”	Dr. Xu Ting (徐霆), the Founder, chairman, executive Director and chief executive officer of our Company
“Dr. Xu’s Family Trust”	a discretionary family trust in the process of establishment by Dr. Xu as settlor for the benefits of Dr. Xu’s family members, of which South Dakota Trust is a trustee

---

## DEFINITIONS

---

“EIT Law”	the PRC Enterprise Income Tax Law (中華人民共和國企業所得稅法), as enacted by the NPC on March 16, 2007 and effective on January 1, 2008, as amended, supplemented or otherwise modified from time to time
“FDA”	the U.S. Food and Drug Administration, a federal agency of the U.S. Department of Health and Human Services responsible for regulating food and drugs
“Founder”	Dr. Xu, the founder of our Group
“Genentech”	Genentech, Inc., an American biotechnology corporation which became a subsidiary of Roche in 2009
“GFA”	gross floor area
“Global Offering”	the Hong Kong Public Offering and the International Offering
“ <b>GREEN</b> Application Form(s)”	the application form(s) to be completed by the <b>White Form eIPO</b> Service Provider, Computershare Hong Kong Investor Services Limited
“Group” or “our Group” or “we”	our Company and all of our subsidiaries or, where the context so requires, any companies that became our subsidiaries as part of the Reorganization and the oncology businesses operated by such subsidiaries or their predecessors, Suzhou Alphamab (as the case may be)
“HCC Investments”	HCC Investments, LLC, a limited liability company incorporated in the United States and one of our Pre-IPO Investors
“Hengrui”	Jiangsu Hengrui Medicine Co., Ltd. (江蘇恒瑞醫藥股份有限公司), a PRC biopharmaceutical company
“HK\$” or “Hong Kong Dollars”	Hong Kong dollars, the lawful currency of Hong Kong
“HKSCC”	Hong Kong Securities Clearing Company Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited

---

## DEFINITIONS

---

“HKSCC Nominees”	HKSCC Nominees Limited, a wholly-owned subsidiary of HKSCC
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Offer Shares”	the 17,942,000 Shares initially offered by our Company for subscription at the Offer Price pursuant to the Hong Kong Public Offering (subject to reallocation as described in “Structure of the Global Offering” of this Prospectus)
“Hong Kong Public Offering”	the offer for subscription of the Hong Kong Offer Shares to the public in Hong Kong at the Offer Price, subject to and in accordance with the terms and conditions set out in this Prospectus and the Application Forms
“Hong Kong Share Registrar”	Computershare Hong Kong Investor Services Limited
“Hong Kong Underwriters”	the underwriters of the Hong Kong Public Offering whose names are set out in “Underwriting—Hong Kong Underwriters” of this Prospectus
“Hong Kong Underwriting Agreement”	the underwriting agreement dated November 29, 2019 relating to the Hong Kong Public Offering entered into by, among other parties, our Company, the Joint Sponsors, the Joint Global Coordinators and the Hong Kong Underwriters
“Hudson Bay”	Hudson Bay Master Fund Ltd., a company incorporated in the Cayman Islands and one of our Pre-IPO Investors
“ICH”	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
“IFRSs”	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
“IND”	investigational new drug or investigational new drug application, also known as clinical trial application in China and clinical trial notification in Australia

---

## DEFINITIONS

---

“Independent Third Party(ies)”	party or parties that, to the best of our Directors’ knowledge, information and belief, having made all reasonable enquiries, is or are not a connected person of the Company within the meaning of the Listing Rules
“Innovent”	Innovent Biologics, Inc. (信達生物製藥), a PRC-based biopharmaceutical company listed on the Main Board of the Stock Exchange (stock code: 01801)
“International Offer Shares”	the 161,461,000 Shares initially offered by our Company for subscription under the International Offering, together, where relevant, with any additional Shares which may be offered by the Company pursuant to the exercise of the Over-allotment Option, subject to reallocation as described in “Structure of the Global Offering” of this Prospectus
“International Offering”	the offer of the International Offer Shares at the Offer Price, in the United States to QIBs only in reliance on Rule 144A and outside the United States in offshore transactions in accordance with Regulation S or any other available exemption from registration under the U.S. Securities Act, as further described in “Structure of the Global Offering” of this Prospectus
“International Underwriters”	the group of international underwriters expected to enter into the International Underwriting Agreement relating to the International Offering
“International Underwriting Agreement”	the international underwriting agreement relating to the International Offering and expected to be entered into by, among other parties, our Company, the Joint Global Coordinators, Joint Bookrunners, Joint Lead Managers and the International Underwriters on or about the Price Determination Date
“Janchor”	Janchor Partners Pan-Asian Master Fund, a company incorporated under the laws of the Cayman Islands and one of our Pre-IPO Investors
“Jiangsu Alphasab”	Jiangsu Alphasab Biopharmaceuticals Co., Ltd. (also known as Jiangsu Alphasab Pharmaceuticals Co., Ltd.) (江蘇康寧傑瑞生物製藥有限公司), a limited liability company established in the PRC on July 14, 2015 and our wholly-owned subsidiary

---

## DEFINITIONS

---

“JLL”	Jones Lang LaSalle Corporate Appraisal and Advisory Limited, the independent property valuer commissioned by us to conduct property valuation on the properties of our Group
“Joint Bookrunners”	Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering), Morgan Stanley & Co. International plc (in relation to the International Offering), CLSA Limited, Jefferies Hong Kong Limited, BOCOM International Securities Limited, Fosun Hani Securities Limited, Orient Securities (Hong Kong) Limited and BOCI Asia Limited
“Joint Global Coordinators”	Morgan Stanley Asia Limited, CLSA Limited and Jefferies Hong Kong Limited
“Joint Lead Managers”	Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering), Morgan Stanley & Co. International plc (in relation to the International Offering), CLSA Limited, Jefferies Hong Kong Limited, BOCOM International Securities Limited, Fosun Hani Securities Limited, Orient Securities (Hong Kong) Limited and BOCI Asia Limited
“Joint Sponsors”	Morgan Stanley Asia Limited, CLSA Capital Markets Limited and Jefferies Hong Kong Limited
“Junshi”	Shanghai Junshi Biosciences Co., Ltd. (上海君實生物醫藥科技股份有限公司), a PRC-based biopharmaceutical company listed on the Main Board of the Stock Exchange (stock code: 01877)
“Kiwi Jolly”	Kiwi Jolly Limited, a business company incorporated in the BVI and one of our Pre-IPO Investors
“KOL(s)”	key opinion leader(s)
“Latest Practicable Date”	November 23, 2019, being the latest practicable date for the purpose of ascertaining certain information contained in this Prospectus prior to its publication
“Listing”	the listing of our Shares on the Main Board
“Listing Committee”	the listing committee of the Stock Exchange



---

## DEFINITIONS

---

“Listing Date”	the date, expected to be on or about December 12, 2019, on which dealings in our Shares first commence on the Main Board
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange. For the avoidance of doubt, the Main Board excludes the Growth Enterprise Market of the Stock Exchange
“MedImmune”	MedImmune, LLC, a pharmaceutical company wholly-owned by AstraZeneca
“Memorandum of Association” or “Memorandum”	memorandum of association of our Company conditionally adopted on November 24, 2019 with effect from the Listing Date
“Merck”	Merck & Co., Inc., a U.S. multi-national pharmaceutical company
“Merck KGaA”	Merck KGaA, or the Merck Group, a German multinational pharmaceutical company
“MOFCOM” or “Ministry of Commerce”	the Ministry of Commerce of the PRC (中華人民共和國商務部)
“MOH”	Ministry of Health (中華人民共和國衛生部), the predecessor of NHFPC
“MOHRSS”	Ministry of Human Resources and Social Security (中華人民共和國人力資源和社會保障部)
“NDRC”	National Development and Reform Commission (中華人民共和國國家發展和改革委員會)
“New Pavillion”	New Pavillion Limited, a company incorporated in the Cayman Islands and one of our Pre-IPO Investors
“NHFPC”	National Health Commission of the PRC (中華人民共和國國家衛生健康委員會)

---

## DEFINITIONS

---

“NIFDC”	National Institute for Food and Drug Control (中國食品藥品檢定研究院)
“NMPA”	the National Medical Products Administration of China (國家藥品監督管理局) or, where the context so requires, its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局), or CFDA
“Non-competition Undertaking”	the non-competition undertaking dated November 24, 2019 and entered into by the Controlling Shareholders in favor of our Company, details of which are set out in “Relationship with Controlling Shareholders” of this Prospectus
“NPCSC”	Standing Committee of the National People’s Congress (全國人民代表大會常務委員會)
“NRDL”	China’s National Reimbursement Drug List
“Offer Price”	the final offer price per Offer Share (exclusive of brokerage fee of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) of not more than HK\$10.20 and expected to be not less than HK\$9.10, such price to be agreed upon by our Company and the Joint Global Coordinators (on behalf of the Underwriters) on or before the Price Determination Date
“Offer Shares”	the Hong Kong Offer Shares and the International Offer Shares
“Over-allotment Option”	the option expected to be granted by our Company to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) pursuant to the International Underwriting Agreement, pursuant to which our Company may be required to allot and issue up to an aggregate of 26,910,000 Offer Shares, representing 15% of the Offer Shares initially being offered under the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any, further details of which are described in “Structure of the Global Offering” of this Prospectus
“PAG Growth”	PAG Growth I (BVI) Limited, a business company incorporated under the laws of the BVI and one of our Pre-IPO Investors

---

## DEFINITIONS

---

“Pearlmed”	Pearlmed Ltd., a company incorporated in the BVI on March 22, 2018 and wholly owned by Mr. Xue Chuanxiao
“Pfizer”	Pfizer Inc., a US multi-national pharmaceutical corporation
“PRC Legal Adviser”	Commerce & Finance Law Offices, our legal adviser as to PRC laws
“PRDL”	Provincial Reimbursement Drug List
“Pre-IPO Investment(s)”	the pre-IPO investment(s) in our Company, the details of which are set out in “History, Reorganization and Corporate Structure—The Pre-IPO Investments”
“Pre-IPO Investors”	the investors of Pre-IPO Investments
“Pre-IPO Share Option Plans”	the pre-IPO share option plan I adopted by our Company on October 16, 2018, which was further amended on March 29, 2019 and the pre-IPO share option plan II adopted by our Company on March 29, 2019, as amended from time to time, the principal terms of which are set out in “Appendix V—Statutory and General Information—D. Pre-IPO Share Option Plans” to this Prospectus
“Preferred Shares”	the Series A Preferred Shares and the Series B Preferred Shares
“Price Determination Agreement”	the agreement to be entered into between our Company and the Joint Global Coordinators (for themselves and on behalf of the Underwriters) on the Price Determination Date to record and fix the Offer Price
“Price Determination Date”	the date, expected to be on or about December 5, 2019 on which the Offer Price is to be fixed by agreement between us and the Joint Global Coordinators (for themselves and on behalf of the Underwriters)
“Property Valuation Report”	the text of a letter, the summary of values and valuation certificates from Jones Lang LaSalle Corporate Appraisal and Advisory Limited, as set out in Appendix III to this Prospectus
“Prospectus”	this prospectus being issued in connection with the Hong Kong Public Offering

---

## DEFINITIONS

---

“QIB”	a qualified institutional buyer within the meaning of Rule 144A
“Regulation S”	Regulation S under the U.S. Securities Act
“Renminbi” or “RMB”	the lawful currency of the PRC
“Reorganization”	the reorganization undergone by our Group in preparation for the Listing as described in the section headed “History, Reorganization and Corporate Structure—Reorganization”
“Roche”	F. Hoffmann-La Roche AG, a Swiss multi-national healthcare company
“Rubymab”	Rubymab Ltd., a company incorporated in the BVI on March 22, 2018 and wholly owned by Dr. Xu
“Rule 144A”	Rule 144A under the U.S. Securities Act
“SAFE”	the State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
“SAIC”	the State Administration of Industry and Commerce of the PRC (中華人民共和國國家工商行政管理總局)
“SAT”	the State Administration of Taxation of the PRC (中華人民共和國國家稅務總局)
“Series A Investors”	holder(s) of the Series A Preferred Shares
“Series A Preferred Shares”	the convertible series A preferred shares with a par value of US\$0.00001 per share in the authorized share capital of the Company allotted and issued to the Series A Investors during the Pre-IPO Investments, or the series A preferred shares with a par value of US\$0.000002 per share held by the Series A Investors in the authorized share capital of the Company following the Share Subdivision, details of which are described in the section headed “History, Reorganization and Corporate Structure”
“Series B Investors”	holder(s) of the Series B Preferred Shares

---

## DEFINITIONS

---

“Series B Preferred Shares”	the convertible series B preferred shares with a par value of US\$0.00001 per share in the authorized share capital of the Company allotted and issued to the Series B Investors during the Pre-IPO Investments, or the series B preferred shares with a par value of US\$0.000002 per share held by the Series B Investors in the authorized share capital of the Company following the Share Subdivision, details of which are described in the section headed “History, Reorganization and Corporate Structure”
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
“Share(s)”	ordinary shares in the share capital of our Company of US\$0.000002 each
“Share Subdivision”	the subdivision of each share in the Company’s issued and unissued share capital with par value of US\$0.00001 each into five shares of the corresponding class with par value of US\$0.000002 each on November 24, 2019, the details of which are set out in “History, Reorganization and Corporate Structure”
“Shareholder(s)”	holder(s) of the Share(s) of our Company
“Shareholders Agreement”	shareholders agreement dated May 27, 2019 entered into among our Company and its subsidiaries, Dr. Xu, Rubymab, Mr. Xue Chuanxiao, Mr. ZHANG Xitian, Mr. Mike Liu, Pearlmed, Sky Diamond, Aljade, the Series A Investors and the Series B Investors
“Sky Diamond”	Sky Diamond Co., Ltd., a company incorporated in the BVI on June 1, 2018 and wholly owned by Mr. ZHANG Xitian
“Sophisticated Investor”	has the meaning ascribed to it under Guidance Letter HKEX-GL92-18 issued by the Stock Exchange
“South Dakota Trust”	South Dakota Trust Company LLC, the trustee of Dr. Xu’s Family Trust
“Southern Creation”	Southern Creation Limited, a special purpose vehicle registered in the BVI and one of our Pre-IPO Investors

---

## DEFINITIONS

---

“Stabilizing Manager”	Morgan Stanley Asia Limited
“State Council”	State Council of the PRC (中華人民共和國國務院)
“Stock Borrowing Agreement”	the stock borrowing agreement to be entered into between Rubymab and Morgan Stanley & Co. International plc on or around the Price Determination Date
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“substantial shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Sunshine Lake”	Sunshine Lake Pharma Co., Ltd. (廣東東陽光藥業有限公司), our collaboration partner to develop a new anti-tumor combination therapy
“Suzhou Alphamab”	Suzhou Alphamab Co., Ltd. (蘇州康寧傑瑞生物科技有限公司), a limited liability company established in the PRC on November 6, 2008 and our connected person
“Suzhou Dingfu”	Suzhou Dingfu Target Biotechnology Co., Ltd. (蘇州丁孚靶點生物技術有限公司), a limited liability company established in the PRC on December 2, 2011
“Takeovers Code”	the Code on Takeovers and Mergers issued by the SFC, as amended, supplemented or otherwise modified from time to time
“Track Record Period”	the two years ended December 31, 2017 and 2018 and the six months ended June 30, 2019
“Umbrella IND”	pursuant to the Announcement of the NMPA Concerning Several Policies on Drug Registration Evaluation and Approval (國家食品藥品監督管理總局關於藥品註冊審評審批若干政策的公告) issued by the NMPA on November 11, 2015, the IND approval for new drugs shall be an overall approval of all phases of a new drug’s clinical trials, instead of a phase-by-phase approval for each phase of a new drug’s clinical trial
“Underwriters”	the Hong Kong Underwriters and the International Underwriters

---

## DEFINITIONS

---

“Underwriting Agreements”	the Hong Kong Underwriting Agreement and the International Underwriting Agreement
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“U.S. Securities Act”	United States Securities Act of 1933, as amended, supplemented or otherwise modified from time to time
“U.S. dollar(s),” “US\$” or “USD”	United States dollars, the lawful currency of the United States
“USPTO”	United States Patent and Trademark Office
“VAT”	value-added tax; all amounts are exclusive of VAT in this Prospectus except where indicated otherwise
“we” “us” or “our”	the Company or the Group, as the context requires
“ <b>WHITE</b> Application Form(s)”	the applicable form(s) for the Hong Kong Offer Shares for use by the public who require(s) such Hong Kong Offer Shares to be issued in the applicant’s own name
“ <b>White Form eIPO</b> ”	the application for Hong Kong Offer Shares to be issued in the applicant’s own name by submitting applications online through the designated website of <b>White Form eIPO</b> Service Provider at <a href="http://www.eipo.com.hk">www.eipo.com.hk</a>
“ <b>White Form eIPO</b> Service Provider”	Computershare Hong Kong Investor Services Limited
“Worldwide Healthcare”	Worldwide Healthcare Trust PLC, a closed-end fund incorporated in the United Kingdom and one of our Pre-IPO Investors
“ <b>YELLOW</b> Application Form(s)”	the application form(s) for use by the public who require(s) such Hong Kong Public Offer Shares to be deposited directly into CCASS

Certain amounts and percentage figures included in this Prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them.

For ease of reference, the names of the PRC laws and regulations, governmental authorities, institutions, natural persons or other entities (including certain of our subsidiaries) have been included in the Prospectus in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail. English translations of official Chinese names are for identification purpose only.